Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Observer-Blinded, Phase I Study to Assess the Safety and Immunogenicity of Vi-DT Conjugate Vaccine Compared to Vi-Polysaccharide (Typhim Vi®, Sanofi Pasteur) Typhoid Vaccine in Healthy Filipino Adults and Children

Trial Profile

A Randomized, Observer-Blinded, Phase I Study to Assess the Safety and Immunogenicity of Vi-DT Conjugate Vaccine Compared to Vi-Polysaccharide (Typhim Vi®, Sanofi Pasteur) Typhoid Vaccine in Healthy Filipino Adults and Children

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Typhoid vaccine Vi DT conjugate International Vaccine Institute/Incepta/SK Bioscience/PT Biofarma (Primary) ; Influenza virus vaccine; Typhoid vaccine Vi-polysaccharide
  • Indications Typhoid
  • Focus Adverse reactions
  • Most Recent Events

    • 23 May 2018 New trial record
    • 15 May 2018 Results published in the Vaccine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top